2005 Fiscal Year Final Research Report Summary
Development of new molecular target therapy based on anti-angiogenesis in ovarian cancer
| Project/Area Number |
15591747
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kagawa Prefectural College of Health Sciences (2004-2005)
Shimane Medical University (2003) |
|---|
Principal Investigator |
HATA Kohkichi Kagawa Prefectural College of Health Sciences, Faculty of Health Science, Professor, 保健医療学部, 教授 (70180875)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Keywords | epithelial ovarian cancer / Angiopoietin-1 / Angiopoietin-2 / in situ hybridization / mRNA expression / Tie2 / immunohistochemistry |
|---|
| Research Abstract |
The recent discovery of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) has provided novel and important insights into the molecular mechanisms of blood vessel formation. Ang-1 helps to maintain and stabilize mature vessels by promoting interaction between endothelial cells and surrounding support cells, e.g., pericytes. Ang-2 is expressed at sites of vascular remodeling and is believed to antagonize the stabilizing action of Ang-1. In the presence of vascular endothelial growth factor (VEGF), vessel destabilization by Ang-2 has been hypothesized to induce an angiogenic response. However, in the absence of VEGF, Ang-2 leads to vessel regression. Although the exact role of the angiopoietin/Tie2 system remains enigmatic, the available evidence indicates that the angiopoietin/Tie2 system in the presence of VEGF is important for the initiation of angiogenesis and for vascular sprouting in tumor.
The role of angiopoietin/Tie2 system with VEGF in epithelial ovarian cancer has been revealed by molecular biological analysis. A new insight to understand the biology of epithelial ovarian cancer might lead to development of a new molecular target therapy for epithelial ovarian cancer.
|
